Trial Profile
A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Apr 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms PRONOMOS
- 29 Mar 2020 Results published in the New England Journal of Medicine
- 29 Mar 2020 According to a Bayer media release, data were published in The New England Journal of Medicine and presented during a virtual session of the American College of Cardiology 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual) .
- 20 Mar 2020 According to a Janssen media release, data will be presented at the virtual American College of Cardiology's 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020.